Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
| Autor: | Vila, Greisa, Luger, Anton, van der Lely, Aart Jan, Neggers, Sebastian J. C. M. M., Webb, S. M.., Biller, Beverly M. K., Valluri, Srinivas, Hey-Hadavi, Judith, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | Internal Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty hypertension Endocrinology Diabetes and Metabolism Pegvisomant 030209 endocrinology & metabolism Context (language use) Hypopituitarism 030204 cardiovascular system & hematology lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Endocrinology cardiovascular disease Diabetes mellitus Internal medicine Acromegaly medicine Humans Risk factor Mortality pegvisomant Original Research Retrospective Studies lcsh:RC648-665 business.industry Human Growth Hormone Middle Aged medicine.disease Cardiovascular disease Prognosis mortality Survival Rate Blood pressure hypopituitarism Cardiovascular Diseases Case-Control Studies Cohort Hypertension Female business medicine.drug Follow-Up Studies |
| Zdroj: | Frontiers in Endocrinology Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Frontiers in Endocrinology, 11:577173. Frontiers Media S.A. r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Frontiers in Endocrinology, Vol 11 (2020) |
| ISSN: | 1664-2392 |
| Popis: | ContextHypertension is a major cardiovascular risk factor related to increased mortality in acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV) treatment in patients with hypertension. This analysis evaluates outcomes in patients with hypertension and acromegaly included in ACROSTUDY.MethodsACROSTUDY is a global non-interventional surveillance study of long-term treatment with PEGV, monitoring its safety and efficacy. The cohort was retrospectively divided in two subgroups: patients with and without hypertension. Stepwise logistic regression and Kaplan-Meyer analyses were performed for testing predictors of mortality.ResultsThe total cohort included 2,090 patients with acromegaly treated with PEGV who were followed for a median of 6.8 years (range up to 12.1 years). In ACROSTUDY there were 1,344 patients with hypertension (52.3% males). This subgroup was older, had a higher BMI, and higher prevalence of diabetes, hyperlipidemia, and cardiovascular disease (CVD) when compared to patients without hypertension. During ACROSTUDY, 68 deaths were reported in the hypertension cohort, vs 10 in the cohort without hypertension. Both CVD (pConclusionsHypertension is common in patients with acromegaly and significantly increases mortality, especially when there is concomitant CVD. These data suggest that treatment goals should extend beyond IGF-I normalization, and include optimisation of substitution of pituitary deficiencies and scrutinous screening and treatment of CVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|